Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroBo Pharmaceuticals, Inc.

2.36
+0.0000
Volume:- -
Turnover:31.15K
Market Cap:20.33M
PE:-0.55
High:2.36
Open:2.36
Low:2.36
Close:2.36
Loading ...

NeuroBo Pharmaceuticals Raises $20 Million from Share Placement

MT Newswires Live
·
26 Jun 2024

BRIEF-Neurobo Pharmaceuticals Announces Closing Of Up To $70 Million Concurrent Private Placement

Reuters
·
26 Jun 2024

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
26 Jun 2024

BRIEF-Neurobo Pharmaceuticals Announces Up To $70 Mln Concurrent Private Placement And Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
24 Jun 2024

NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering

MT Newswires Live
·
24 Jun 2024

NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering

MT Newswires Live
·
24 Jun 2024

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
24 Jun 2024

NeuroBo Pharmaceuticals: Warrants Expected to Provide Cash Runway to Complete Phase 1 Part 3 Clinical Trial

THOMSON REUTERS
·
24 Jun 2024

Press Release: NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dow Jones
·
24 Jun 2024

NeuroBo Pharmaceuticals Shares Rise on Positive Results for Weight-Loss Drug

Dow Jones
·
24 Jun 2024

BRIEF-Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority In Weight Loss

Reuters
·
22 Jun 2024

NeuroBo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

THOMSON REUTERS
·
22 Jun 2024

NeuroBo Pharmaceuticals - Da-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide

THOMSON REUTERS
·
22 Jun 2024

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

PR Newswire
·
22 Jun 2024

NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors

TIPRANKS
·
08 Jun 2024